ABSTRACT
Objective. To evaluate the efficacy of a benzydamine-containing drug in children with COVID-19. Patients and methods. This observational randomized study included 88 children with confirmed mild or moderate COVID-19. The experimental group comprised 44 children who received drugs containing benzydamine, whereas the control group comprised 44 children who received other local treatments. The groups were matched for age, sex, disease severity, main manifestations, and systemic therapy received. Results. Children in the experimental group demonstrated faster recovery than those from the control group (after 6.20 ± 2.93 days vs 7.36 ± 3.17 days, respectively;р < 0.05). Virus elimination occurred earlier in children receiving benzydamine than in controls (3.93 ± 2.48 days vs 5.27 ± 3.64 days, respectively;р < 0.05. Benzydamine significantly reduced the duration of pharyngeal hyperemia (by 2.29%), sore throat (by 1.77 days;р < 0.05), and fever (by 0.93 days;р < 0.05) compared to other local treatments. Conclusion. Benzydamine significantly increases the efficacy of COVID-19 treatment.
ABSTRACT
Introduction. The article presents basic information on approaches to pathogenetic therapy of acute intestinal infections. Data from our own research on the diagnosis and treatment of gastrointestinal manifestations of COVID-19 in children aged 3 months to 18 years are presented. The aim of the study was to evaluate the effectiveness of complex rehydration, cytomucoprotective and probiotic therapy for infectious diarrhea of various etiologies, including those developing with a new coronavirus infection. Materials and methods. We analyzed data from our own observations of patients aged 3 months to 18 years with diarrhea against the background of acute intestinal infections of various etiologies (120 children), as well as with a new coronavirus infection caused by the SARS-CoV-2 virus (32 children). The children were treated in accordance with current standards and treatment recommendations. Clinical examples are presented. Results and discussion. Diarrhea was observed in 64% of patients with a new coronavirus infection. Clinical cases confirm the effectiveness of rehydration, cytomucoprotective and probiotic therapy for infectious diarrhea, regardless of the etiology, including COVID-19. Conclusions. Diarrhoea and other symptoms of gastrointestinal disorders in COVID-19 are stopped when pathogenetic therapy is recommended for patients with acute intestinal infections. © 2020, Remedium Group Ltd. All rights reserved.
ABSTRACT
Objective of the work was to investigate the peculiarities of gastrointestinal tract disorders in children with coronavirus disease caused by SARS-CoV-2 virus. Materials and methods. We have analyzed the frequency, terms of emergence, duration and character of gastrointestinal disorders on the basis of medical records of 36 children receiving the treatment for community-acquired pneumonia of coronavirus etiology (positive for SARS-CoV-2 virus) in the children’s infectious disease department of Moscow State Clinical Hospital, Mytishchi. The majority of patients had moderate form of the disease (97 %), severe cases were not registered. The age range of the children – 8 months to17 years old. All patients were subjected to supplementary examination on Day 1 in accordance with the current recommendations. Children were treated in hospital settings for 8–15 days. Assessment of clinical status was performed at least once a day over the stated period, supplementary survey – at least once in a week, upon indications – more frequently. SARSCoV-2 virus was identified using polymerase chain reaction. All patients received standard therapy in compliance with advanced methodological recommendations, upon indications – other pharmaceutical products. Results and discussion. Gastro-intestinal disorders in 23 children (64 %) emerged on Day 4–5, in 8 children (22 %) – before the start of the treatment;they lasted 3–5 days. In most of the patients diarrhea (64 %) and stomachaches (57 %) were observed. 67 % of the children demonstrated other symptoms indicative of gastrointestinal dysfunction. The disorders were characteristic for most of the children hospitalized with community-acquired pneumonia caused by SARS-CoV-2 virus. The symptoms are contained when the main course of therapy is conducted, indicated for treatment of COVID-19, and additional therapy recommended for management of gastro-intestinal infections is performed. © 2020 Russian Research Anti-Plague Institute. All rights reserved.